Perlmutter Cancer Center

The purpose of the study is to evaluate the safety, efficacy and tolerability of one or more experimental arms for the treatment of advanced renal cell carcinoma (RCC). There are specific set of treatment arms and these arms are composed of investigational agents. The experimental arms include the following: MK-1308A+ Lenvatinib, MK-4280A + Lenvatinib, Pembrolizumab + Lenvatinib + MK-483, and Pembrolizumab + Lenvatinib + MK-6482. The reference arm includes Pembrolizumab + Lenvatinib. The combination of these investigational agents in the trial has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test these agents in the current trial.